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Irritable bowel syndrome (IBS) may be associated with disturbances in gut microbiota 43	
composition and functions. We recently performed a study of fecal microbiota 44	
transplantation (FMT) in diarrhea-predominant IBS (IBS-D) and found that IBS 45	
symptoms improved and the gut microbiota profile changed following FMT.  46	
We now aimed to explore the effects of FMT on the gut microenvironment in further 47	
detail by using 16S rRNA sequencing for more extended microbiota profiling and 48	
analyzing bacterial fermentation products (SCFAs: short chain fatty acids). 49	
 50	
	 3	
Materials and methods 51	
The study included 13 patients (4 females and 9 males) with IBS-D according to 52	
Rome III criteria and 13 healthy donors. Freshly donated feces were administered into 53	
duodenum via gastroscopy. The patients completed symptom and quality of life 54	
(QoL) questionnaires and delivered feces before and 1, 3, 12 and 20/28 weeks after 55	
FMT. Microbiota analysis was performed by sequencing 16S rRNA gene with 56	
Illumina Miseq technology. Fecal concentrations of SCFAs were analyzed by vacuum 57	
distillation followed by gas chromatography.  58	
 59	
Results  60	
Several gut microbiota taxa and SCFAs were significantly different in the patients at 61	
baseline compared to their donors. These differences normalized by the third week 62	
following FMT in parallel with significant improvement in symptoms and QoL. 63	
Responders had different gut microbiota profile and SCFAs than non-responders. 64	
Significant correlations were found between the gut microenvironment and IBS 65	
symptoms. No adverse effects were reported. 66	
 67	
Conclusions  68	
FMT restores alterations of the gut microenvironment in IBS-D patients during the 69	








Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) disorder 77	
with unclear pathogenesis. It may be associated with disturbances of gut microbiota 78	
composition and functions such as bacterial fermentation [1]. The role of gut 79	
microbiota alterations in IBS has led to increased interest in using probiotic [2] and 80	
antibiotic [3] approaches for improving IBS symptoms [2]. 81	
 82	
It has been proposed that feces from a healthy human donor may constitute “the 83	
ultimate human probiotic” [4]. The infusion of fecal preparations from a healthy 84	
donor into the GI tract of a human recipient, known as fecal microbiota 85	
transplantation (FMT), has been used to alter the gut microbiome by re-establishing 86	
the balance in the gut microbiota of the new host [4]. Therefore, FMT has been 87	
suggested as a treatment option for conditions where an altered gut microbiota has 88	
been detected, including IBS [4]. Currently, FMT is widely accepted as the 89	
recommended treatment for recurrent Clostridium difficile enterocolitis [5]. New data 90	
suggest that FMT is effective in improving the symptoms of IBS [6-9] and is 91	
associated with changes in the gut microbiota [9, 10]. However, the underlying 92	
mechanisms are yet to be explored.  93	
The gut microbiota in the colon ferments unabsorbed food residues, mostly 94	
carbohydrates, to short-chain fatty acids (SCFAs) – mainly acetic acid, propionic 95	
acid, and n-butyric acid. SCFAs stimulate blood flow, fluid and electrolytes uptake in 96	
the colon, and are preferred energy substrates for the colonocytes (i.e. n-butyric acid) 97	
[11]. Previous studies of fecal SCFAs in IBS have shown conflicting results [12, 13].  98	
 99	
We recently performed a study of FMT in diarrhea-predominant IBS (IBS-D) and 100	
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found that the symptoms improved in 75%, 85% and 65% of the total group at 1, 3 101	
and 20/28 weeks after FMT, respectively [9]. In addition, the patients’ quality of life 102	
and their stool form improved parallel to changes in their gut microbiota [9]. 103	
We now aimed to explore the effects of FMT on gut microenvironment in further 104	
detail by analyzing bacterial fermentation products (SCFAs) and more extended 105	
microbiota profiling with 16S rRNA sequencing, with a particular focus on patients 106	
responding to FMT compared with non-responders. 107	
 108	
Material and methods 109	
Participants 110	
During the year of 2015, patients who were referred to the gastroenterology outpatient 111	
clinic, Haukeland University Hospital, Bergen, Norway, age between 18-70 years, 112	
with a diagnosis of IBS according to the Rome III criteria, were included in the study. 113	
Patients who scored >175 on the IBS-Symptom Severity Scoring system (IBS-SSS) 114	
questionnaire, which indicates moderate to severe symptom severity [14] were 115	
included. The exclusion criteria were previous abdominal surgery, current pregnancy 116	
or lactation, and probiotics or antibiotics treatment within 4 weeks prior to fecal 117	
installation. Patients with a history of blood in stool, inflammatory bowel disease, an 118	
immunocompromised state, GI malignancy, a history of opportunistic infections 119	
within 1 year prior to FMT, oral thrush, or disseminated lymphadenopathy were also 120	
excluded.  121	
The donor group included healthy family members of both genders above 18 years of 122	
age.  The exclusion criteria for the donors were pregnancy, history of diarrhea, blood 123	
in stool, inflammatory bowel disease, IBS, chronic abdominal pain, GI malignancy, 124	
antibiotic and probiotic use within 4 weeks prior to FMT, an immunocompromised 125	
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The participants’ demographic characteristics have been described in details 130	
previously [9]. In brief, the patients were scheduled for several visits; the first was 131	
scheduled for screening tests one week before the FMT procedure (screening), 132	
followed by the day of the FMT procedure (baseline), and then 4 control visits 133	
(control 1−4) at weeks 1, 3, 12 and 28 weeks, respectively, after FMT. The screening 134	
program included physical examination, and blood and stool tests (for previous 135	
exposure to contagious infectious agents, inflammation and other organic diseases) 136	
for both donors and patients one week before FMT as described previously [9].  137	
The patients completed self-report questionnaires and delivered fresh stool samples 138	
collected in containers soon after defecation at each visit before and after FMT. Stool 139	
samples were temporarily stored in the refrigerator at home (4°C) before delivery to 140	
our unit where they will be permanently stored in refrigerator at -80°C until analysis. 141	
The patients were informed not to change their diet or life style throughout the study 142	
and to immediately report health changes and/or use of new medications (if any) at 143	
any point during the study.  144	
 145	
The FMT procedure. Both donors and patients brought >60 g of fresh feces on the 146	
FMT day [9]. Thirty grams of freshly donated feces [15] from the donors were 147	
manually mixed with 60 ml of normal saline and sieved in order to avoid any hard 148	
particles during the preparation of the fecal suspension just before the gastroscopy 149	
procedure. After an overnight fast, gastroscopy was performed and 60 ml of the fecal 150	
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suspension was instilled, only once, in the descending part of the duodenum distal to 151	
the papilla Vateri, followed by 60 ml normal saline. The remaining feces from donors 152	
and patients were stored at –80°C until the time for analysis. T.M., G.A.L. or T.H. 153	
performed the procedures at the endoscopy unit, Haukeland University Hospital, 154	
Bergen, Norway. Control visits 1–4 were planned at weeks 1, 3, 12 and 28, 155	
respectively, after the FMT procedure when the patients delivered fecal samples for 156	
storage at –80°C until analyses.  157	
 158	
Analysis of SCFAs. An amount of 0.5 g of fecal material was homogenized 159	
following the addition of distilled water containing 3 mmol/L of 2-ethylbutyric acid 160	
(as internal standard) and 0.5 mmol/L of H2SO4; 2.5 mL of the homogenate was 161	
vacuum distilled, according to the method of Zijlstra et al. [16] as modified by 162	
Hoverstad et al. [17]. The distillate was analyzed with gas chromatography (Agilent 163	
7890 A; Agilent, CA, USA) using a capillary column (serial no. USE400345H, 164	
Agilent J&W GC columns; Agilent, CA, USA) and quantified using internal 165	
standardization. Flame ionization detection was employed. Fecal concentrations of 166	
major SCFAs (acetic, propionic and n-butyric acids) and minor SCFAs (iso-butyric, 167	
n-valeric, iso-valeric, n-caproic and iso-caproic acids) were analyzed. The results 168	
were expressed in mmol/kg wet weight. 169	
 170	
Analysis of gut microbiota composition. Bacterial DNA were extracted from stool 171	
using MoBio PowerSoil DNA extraction kit, and submitted to sequencing of the V3-172	
V4 regions of the 16S rRNA gene according an established protocol using the 173	
Illumina Miseq [18]. Quality control and processing of the raw reads were performed 174	
with the QIIME (qiime.org) open source software package [19]. Measures of intra-175	
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individual (alpha) diversity as well as relative abundance of bacteria on different 176	
taxonomic levels (from phylum to genus level) were calculated. Alpha diversity was 177	
evaluated using index of diversity (Shannon) [20] and index of richness (Chao1) [21, 178	
22]. 179	
 180	
Symptom questionnaires. Symptoms were evaluated using IBS-SSS [14]. Patients 181	
with reduced IBS-SSS scores ≥50 points at week 28 compared to baseline were 182	
defined as responders and those who achieved <50 points were defined as non-183	
responders [14]. The IBS-SSS questionnaire was completed at all time points. In 184	
addition, IBS symptom questionnaire (IBS-SQ) [23, 24] was completed on the 185	
screening day before FMT and then daily for 20 days after FMT. Stool consistency 186	
was evaluated using Bristol stool form scale [25], ranging from 1 (constipation) to 7 187	
(diarrhea). Quality of life (QoL) was assessed at baseline and control visits 2 and 4, 188	
using Short Form of Nepean Dyspepsia Index (SF-NDI) questionnaire where 189	
higher/lower scores represent worse/improved QoL, respectively [26].  190	
 191	
Statistical analysis 192	
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) was used for 193	
statistical analyses. Repeated measures one-way ANOVA with Holm-Sidak's multiple 194	
comparisons test was used to analyse the patients’ symptoms before and after FMT. 195	
Kruskal-Wallis non-parametric test with Dunn’s post test was used to analyse the 196	
microbiota and SCFA data between the donors and patients before and after FMT. 197	
Multiple t-tests were used to compare between responders and non-responders. The 198	
data are presented as the mean ± standard error of mean (SEM). Spearman’s test was 199	
used to study the correlations between the symptoms and variables of the gut 200	
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The study was performed in accordance with the Declaration of Helsinki [27] and was 205	
approved by the Regional Committee for Medical and Health Research Ethics in 206	
Western Norway (reference number: 2013/1497). All of the participants were adults 207	
(>18 years old) and provided written informed consent. This study was registered at 208	
ClinicalTrials.gov (ID: NCT03333291). 209	
 210	
Results 211	
Participants   212	
Sixteen patients were included in the current study. Three patients were excluded after 213	
being diagnosed with functional dyspepsia (n=1) and Clostridium difficile 214	
enterocolitis during stool screening (n=1) and withdrawing the consent to participate 215	
due to personal reasons (n=1), as previously reported [9]. Hence 13 patients (9 males 216	
and 4 females, mean age of 32 years (range 20–44 years) and 13 donors (6 males and 217	
7 females, mean age of 33 years (range of 20–42 years) completed the whole study. 218	
Four patients and their respective donors had their last control visit scheduled eight 219	
weeks earlier than the original date (28 weeks following FMT according to the 220	
original protocol [9]) for practical reasons.  221	
The results from the screening blood tests and stool cultures at baseline for both the 222	
donors and the patients were normal and control blood tests for the patients at the end 223	
of the study were also normal. The patients and donors did not report any changes in 224	




IBS-SSS score (mean±SEM) for the asymptomatic donors was 18±8.9 and the scores 228	
for the total group of IBS patients at baseline (week 0) and at the last week of the 229	
study were 328.8±20.7 and 250.8±35.9, respectively. According to clinical response 230	
at week 20/28, eights patients were considered responders (IBS-SSS reduction >50 231	
from baseline) and five non-responders. The IBS-SSS scores for the responders and 232	
non-responders’ groups were similar at baseline and control visit 1, but was 233	
significantly reduced compared to baseline only for the responders’ group from 234	
control visit 2 and onwards (Fig 1). Significant differences were noted in IBS-SSS 235	
scores between the responders and non-responders’ groups at control visit 3 and 4 236	
(Fig 1). Clinical responses before and during the first 20 days after FMT as assessed 237	
by the different domains of IBS-SQ questionnaire in responders and non-responders’ 238	
groups are shown in supplementary 1. The responders’ group showed improved 239	
quality of life scores as measured by SF-NDI at control visits 2 and 4 compared to 240	
baseline (P=0.036 and 0.0095, respectively), while no improvement was shown in the 241	
non-responders’ group, supplementary 2. Stool consistency also improved from 242	
watery to normal in the responders’ group (Bristol stool scale scores changing from 243	
5.4±0.6 at baseline to 3.6±0.6 at control visit 4), while it remained unchanged for the 244	
non-responders’ group.  245	
 246	
Bacterial fermentation products (SCFAs) 247	
SCFAs were analyzed in all available stool samples at all time points. Before FMT, 248	
the concentrations of several SCFAs were significantly lower in IBS patients 249	
compared to the donors (Table 1). After FMT, the concentrations of SCFAs in IBS 250	
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patients increased and became non-significantly different from that of the donors at 251	
control visit 2, and the increment lasted up to the end of the study (Table 1).  252	
Looking into subgroups, only the responders showed a significant difference when 253	
comparing the concentrations of the iso-butyric acid at baseline and control visit 1 to 254	
the donors (P=0.003 and 0.049, respectively), valeric acid at baseline to donors 255	
(P=0.0085), iso-valeric acid at baseline and control visit 1 to donors (P=0.002 and 256	
0.03, respectively), Fig. 2.  257	
 258	
Gut microbiota composition of the patients 259	
The trajectories of the intra-individual (alpha) diversity of gut microbiota of IBS 260	
patients from baseline and after FMT are shown in comparison with the donors in Fig 261	
3 (A and B). The diversity in the total group of IBS patients at baseline was 262	
numerically lower than that of the donors, but statistically non-significant, and 263	
increased towards the levels of the donors following FMT. The diversity of gut 264	
microbiota in the responders and non-responders’ groups showed similar changing 265	
patterns, Fig 3 (A and B). 266	
The abundance of gut microbes on phylum level in donors and patients during the 267	
course of the study is shown in Fig 4. The total group of IBS patients had significantly 268	
different gut microbial composition than their donors at baseline before FMT (Table 269	
2). On phylum level, Actinobacteria was less abundant in IBS patients, which was 270	
primarily driven by the genus Bifidobacterium. Additional genera differing between 271	
donors and patients were Ruminococcus gnavus, Clostridium sensu stricto, and 272	
Gardnerella. The abundance of these four genera became more similar to the donors 273	
from baseline to control visit 2, while at control visit 3 and 4 the abundances became 274	
again significantly different compared with the donors (Table 2). Furthermore, the 275	
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abundance of Bacteroides, Alistipes, Parabacteroides and Pseudomonas became 276	
significantly different in the total group of IBS patients at the end of the study 277	
compared to the donors. An early increase of the phylum Proteobacteria was observed 278	
at control visit 1, peaking far beyond the donor abundance, primarily driven by the 279	
Escherichia-Shigella genus, but the abundance was reduced and no longer different 280	
from the donors at control visit 2 and later.  281	
When investigating subgroups according to treatment response, the responders’ group 282	
showed significant differences between the patients and their donors before FMT for 283	
the Clostridium sensu stricto and Bifidobacterium, which normalized by control visit 284	
2 but some genera became significantly different again towards the end of the study 285	
as shown in Table 3.  286	
In the non-responders’ group, significant differences between the patients and their 287	
respective donors were shown only for Bifidobacterium before FMT and for 288	
Bacteroides, Alistipes and Pseudomonas towards the end of the study as shown in 289	
Table 4. No significant differences were found between the patients and their 290	
respective donors for Akkermansia in any of the groups and for Ruminococcus gnavus 291	
and Gammaproteobacteria in the responders and non-responders’ groups during the 292	
whole study.  293	
 294	
Gut microbiota composition of the donors 295	
The donors were divided according to the patients’ clinical response after receiving 296	
FMT into responders and non-responders and so the analysis of the donors’ data was 297	
performed accordingly. No significant differences were found in the diversity 298	
(Shannon index) and richness (Chao1 index) of the gut microbiota between the donors 299	
of the responders’ group and those of the non-responders’ group. 300	
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 301	
Correlations between gut microbiota variables and IBS symptoms 302	
In the total group of IBS patients an inverse relation is shown between microbial 303	
richness according to Chao1 index and IBS-SSS score during the study period, (Fig 304	
5). Using Spearman test, before FMT in the total group of IBS patients, correlations 305	
were found between IBS symptoms and the gut microenvironment: nausea correlated 306	
with abundance of Clostridium sensu stricto (r=0.70, P=0.043), and diarrhea 307	
correlated with Proteobacteria (r= 0.72, P=0.03) and Escherichia-Shigella  (r= 0.72, 308	
P=0.03). Concentrtion of butyric acid in feces correlated with abundance of 309	
Firmicutes (r=0.79, P=0.016) and Actinobacteria (r= 0.85, P=0.005). The scores for 310	
IBS-SSS correlated with SF-NDI in responders’ group before FMT (r=0.73, P=0.046) 311	
and in non-responders’ group before FMT (r= 1, P=0.02) and after FMT at control 312	
visit 2 (r= 0.97, P=0.03). In addition, scores for Bristol stool form scale correlated 313	
with IBS-SQ-abdominal pain (r=0.79, P=0.02) and diarrhea (r=0.72, P=0.046) in the 314	
responders’ group before FMT and after FMT at control visit 1 (r=0.82, P=0.03 and 315	
r=0.78, P=0.04, respectively).  316	
 317	
Complications 318	
No complications or adverse events were reported or recorded during or following the 319	
FMT procedure or at any point of the study.  320	
 321	
Discussion   322	
The current study investigated the effects of transplanting feces from healthy donors 323	
to IBS patients and focused on exploring the effects on the gut microenvironment by 324	
measuring fecal SCFAs, which are end products of bacterial fermentation, and 325	
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microbiota profiling with 16S rRNA sequencing. The results suggest that both gut 326	
microbiota and SCFAs in IBS patients are different from that of the donors at baseline 327	
and seem to normalize after 3 weeks following FMT in parallel to improved IBS 328	
symptoms and quality of life for the patients during the same period.  329	
 330	
Previous studies have shown that IBS is associated with altered gut microbiota profile 331	
and fecal SCFAs concentrations [1, 12]. In our study, the major SCFA– n-butyric acid 332	
– and several minor SCFAs were significantly different between patients and donors 333	
at baseline.  334	
The major SCFAs are acetic, propionic and n-butyric acids [11] and their levels 335	
depend on factors such as diet, microbiota composition, and host factors such as 336	
orocecal transit time [28]. IBS is associated with altered (either lower [12, 29] or 337	
higher [12, 13]) fecal levels of SCFAs. More abdominal rumbling was noticed for IBS 338	
patients with lower concentrations of SCFAs [12]. These studies suggested using 339	
fecal SCFAs as diagnostic markers for IBS [13, 29]. 340	
In a previous publication, IBS patients were classified according to their acetic acid 341	
levels, high vs. low [1]. In the current study, IBS patents had lower levels of acetic 342	
acids than healthy donors, but it did not reach the level of significance. The branched-343	
chain fatty acids (iso-valeric and iso-butyric acids) are mainly products of protein 344	
degradation, fermented increasingly through progression to the distal colon. They 345	
were found to be significantly different in patients compared to donors at baseline, 346	




In general, IBS patients seem to have low microbial diversity and richness [10, 31], 350	
decreased levels of Actinobacteria and Bifidobacterium [32], and increased levels of 351	
Bacteroidetes and Proteobacteria in the feces [32, 33], which is consistent with our 352	
findings. The microbial diversity, richness and several bacterial genera seem to 353	
normalize following FMT in the total and responders’ groups, which is in line with 354	
previous publications [10, 31], and indicates that FMT alters the gut microbiota [10].  355	
 356	
Actinobacteria and Bifidobacterium are important for mucosal barrier of the gut to 357	
keep pathogens from crossing over [32]. They were present in low levels in IBS 358	
patients at baseline in the current study, which is consistent with a previous 359	
publication [32]. Actinobacteria and Bifidobacterium produce acetic acid during 360	
colonic fermentation to be used as substrates by other butyrate-producing bacteria 361	
[34], which may explain the correlations between these bacteria and SCFAs in this 362	
study. Higher levels of n-butyric acid promote the virulence in E. coli and its ability to 363	
colonize the colon, which may explain the increase in Escherichia levels one week 364	
after FMT [35]. The correlations of diarrhea with Escherichia-Shigella and 365	
Proteobacteria are consistent with previous publications [36, 37].  366	
Akkermansia (belongs to Verrucomicrobia phylum) are butyrate-producing bacteria 367	
and have been shown to restore gut barrier function and appropriate tight junction 368	
expression [38]. On the other hand, Ruminococcus gnavus cause degradation of the 369	
mucus layer [32, 39].  Akkermansia correlated positively with Ruminococcus gnavus 370	
[40], both of which were found in higher abundance in our patients at baseline 371	
compared to their donors, which may allow us to speculate whether Akkermansia 372	
levels reflect their gut permeability-protective actions against Ruminococcus gnavus.  373	
 374	
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About 62% of the patients (8/13) were considered as clinical responders by the end of 375	
the study [9]. The inverse relation between the severity of IBS symptoms (IBS-SSS) 376	
and low microbial richness (Fig 5) is consistent with previous publications [41, 42]. 377	
The same observation applies on low microbial diversity and richness, and worsening 378	
of diarrhea [31, 42]. The correlations between IBS-SSS and quality of life and 379	
between IBS-SQ-abdominal pain and diarrhea with Bristol stool form scale are 380	
consistent with previous publications [10, 14, 25, 42, 43]. The improvement in the 381	
stool form as evaluated by Bristol stool form scale following FMT has also been 382	
observed in a previous study [31]. 383	
 384	
Several techniques have been described for the laboratory preparation of fecal 385	
suspension and can be classified into rough filtration, filtration plus centrifugation, 386	
and microfiltration plus centrifugation [44, 45]. The method used in the current study 387	
i.e. 30 g of feces that have been manually suspended in saline and sieved in order to 388	
avoid the clogging of infusion syringes and tubes) is consistent with the European 389	
consensus on FMT in clinical practice [15]. In the current study, the patients received 390	
FMT only once. The time intervals for repeated FMT is crucial and might affect the 391	
clinical outcome but at the time being it is still unknown what is the best time interval 392	
for repeated FMT procedures and future research should focus on this point.  393	
 394	
A meta-analysis of four randomized control trials comparing FMT to placebo (either 395	
autologous FMT or other) show conflicting results regarding the effect of FMT on 396	
IBS symptoms and concludes that current evidence does not suggest a benefit of FMT 397	
for global IBS symptoms [46]. However, despite the limitations of the current study, 398	
it shows that FMT has positive effects on IBS symptoms that lasts at least 6 months in 399	
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most of the patients who responded to the treatment. The limitations of this study are 400	





results. The strengths of the present study include the simultaneous assessment of 406	







In conclusion FMT helps in restoring the alterations in the gut microbiota and their 414	
functions in IBS patients and improves their symptoms for up to 28 weeks after FMT. 415	
Thus, normalizing both the levels of SCFAs and gut microbiota may be beneficial in 416	
IBS [47]. This study confirms the associations between gut microbiota, SCFAs and 417	
IBS symptoms. 418	
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Fig 1. The scores of IBS-SSS in the responders vs. non-responders’ groups 656	
before (at screening and baseline) and after fecal microbiota transplantation 657	
(control visits 1–4).  658	
 659	
Fig 2. Concentrations of short-chain fatty acids (mmol/kg) for donors and 660	
patients in the responders vs. non-responders’ groups before  (baseline) and 661	
after fecal microbiota transplantation (control visits 1–4).  662	
 663	
Fig 3. Alpha diversity in the responders and non-responders and total groups 664	
of donors and patients with irritable bowel syndrome before (baseline) and 665	
after (control visits 1–4) fecal microbiota transplantation as presented by A) 666	
Shannon index, B) Chao1 index. 667	
 668	
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 Fig 4. Taxonomy levels (%) in total, donors, patients at FMT (baseline) and 669	
control visits 1–4. 670	
 671	
Fig 5. Chao1 index vs. IBS-SSS scores for the total group of IBS patients before 672	




Table 1: Short-chain fatty acids (SCFAs) concentrations (mmol kg-1) in fecal samples 677	
collected from total groups of donors and patients with irritable bowel syndrome 678	


























Acetic acid 33.9±2.8 23.6±6 31.1±4.9 35.5±3.9 25.8±4.4 28.5±2.4 0.77 >0.9 >0.9 0.3 >0.9 
















































































































n-caproic 0.8±0.02 0.3±0.1 0.5±0.2 0.5±0.1 0.2±0.08 0.3±0.09 0.2 >0.9 >0.9 0.059 0.17 
Iso-caproic 0.01±0.005 0.02±0.02 0.008±0.006 0.013±0.01 0.01±0.005 0±0 >0.9 >0.9 >0.9 >0.9 0.6 























Data are presented as mean±SEM. Comparison: Kruskal-Wallis multiple comparisons test with Dunn’s post test. Pbaseline Donors at the beginning of the 
study vs. patients on FMT day before fecal installation, P1 Donors at the beginning of the study vs. patients at 1st control following FMT, P2 Donors at the 
beginning of the study vs. patients at 2nd control following FMT, P3 Donors at the beginning of the study vs. patients at 3rd control following FMT, P4 Donors 
at the beginning of the study vs. patients at 4th control following FMT. FMT: fecal microbiota transplantation. SCFAs: short-chain fatty acids. 
 680	
 681	
Table 2:  Gut microbiota differences in the total group between donors at 682	
baseline and IBS patients before and at each control visit after fecal microbiota 683	
transplantation. The left part of the table shows the microbial taxa for donors and 684	
patients before fecal microbiota transplantation (FMT) and at each control visit after 685	
FMT and the directionality towards or away from that of the donors at baseline. The 686	
right part of the table shows the P-values when comparing the different microbial 687	







































































































9 0.04 0.03 
Clostridium 




































































































Data are presented as the mean±SEM. Comparison: Kruskal-Wallis multiple comparisons test with Dunn’s post test: Pbaseline Donors at the beginning of 
the study vs. patients on FMT day before fecal installation, P1 Donors at the beginning of the study vs. patients at 1st control following FMT, P2 Donors 
at the beginning of the study vs. patients at 2nd control following FMT, P3 Donors at the beginning of the study vs. patients at 3rd control following FMT, 
P4 Donors at the beginning of the study vs. patients at 4th control following FMT. FMT: fecal microbiota transplantation. 
 689	
Table 3:  Gut microbiota differences in the responders’ group between donors at 690	



































































Data are presented as the mean±SEM. Comparison: Kruskal-Wallis multiple comparisons test with Dunn’s post test: Pbaseline Donors at the beginning of the 
	 27	
study vs. patients on FMT day before fecal installation, P1 Donors at the beginning of the study vs. patients at 1st control following FMT, P2 Donors at the 
beginning of the study vs. patients at 2nd control following FMT, P3 Donors at the beginning of the study vs. patients at 3rd control following FMT, P4 
Donors at the beginning of the study vs. patients at 4th control following FMT. FMT: fecal microbiota transplantation. 
 693	
Table 4: Gut microbiota differences in the non-responders’ group between donors at 694	




























>0.9 0.02 0.2 






e-005 0.0003±0.0002 0 0 
0.086 0.2 >0.9 
0.03 0.046 
Data are presented as the mean±SEM. Comparison: Kruskal-Wallis multiple comparisons test with Dunn’s post test: Pbaseline Donors at the beginning of the 
study vs. patients on FMT day before fecal installation, P1 Donors at the beginning of the study vs. patients at 1st control following FMT, P2 Donors at the 
beginning of the study vs. patients at 2nd control following FMT, P3 Donors at the beginning of the study vs. patients at 3rd control following FMT, P4 




Suppl. 1. The scores of IBS-SQ in the responders vs. non-responders’ groups 700	
one week before and daily for 20 days after fecal microbiota transplantation in 701	
the different domains: a) nausea, b) bloating, c) abdominal pain, d) 702	
constipation, e) diarrhea and f) anorexia/loss of appetite. 703	
 704	
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Suppl. 2. Short form- Nepean dyspepsia index (SF-NDI) scores in responders 705	
and non-responders patients with irritable bowel syndrome before and after 706	
fecal microbiota transplantation. 707	
 708	
